The Role of the 'Lifestyle' Label and Negative Bias in the Allocation of Health Resources for Erectile Dysfunction Drugs: An Ethics-Based Appraisal
International Journal of Impotence Research 2006 January-February; 18(1): 98-103. Erratum in: International Journal of Impotence Research 2006 March-April; 18(2): 221
Showing items related by title, author, creator and subject.
Where Cost, Medical Necessity, and Morality Meet: Should US Government Insurance Programs Pay for Erectile Dysfunction Drugs? Polinski, J M; Kesselheim, A S (2011-01)Spending for the three most popular phosphodiesterase (PDE) inhibitor drugs to treat erectile dysfunction (ED) tops $1 billion worldwide annually. Using Medicaid and Medicare Part D as examples, we explore here whether US ...